Abbott, the creator of continuous glucose monitors, launched the new Assist feature at CES 2026. Part of the Libre app, it ...

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...

In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S.

Abbott Laboratories (ABT) has drawn fresh attention after unveiling Libre Assist, an AI driven feature in its Libre app that ...

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers ...

Abbott has launched Libre Assist, a feature within the Libre app designed to help people living with diabetes better understand how the foods they eat affect their glucose levels.

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed.